265 related articles for article (PubMed ID: 34788506)
1. Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome.
Gentner B; Tucci F; Galimberti S; Fumagalli F; De Pellegrin M; Silvani P; Camesasca C; Pontesilli S; Darin S; Ciotti F; Sarzana M; Consiglieri G; Filisetti C; Forni G; Passerini L; Tomasoni D; Cesana D; Calabria A; Spinozzi G; Cicalese MP; Calbi V; Migliavacca M; Barzaghi F; Ferrua F; Gallo V; Miglietta S; Zonari E; Cheruku PS; Forni C; Facchini M; Corti A; Gabaldo M; Zancan S; Gasperini S; Rovelli A; Boelens JJ; Jones SA; Wynn R; Baldoli C; Montini E; Gregori S; Ciceri F; Valsecchi MG; la Marca G; Parini R; Naldini L; Aiuti A; Bernardo ME;
N Engl J Med; 2021 Nov; 385(21):1929-1940. PubMed ID: 34788506
[TBL] [Abstract][Full Text] [Related]
2. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
3. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome.
Wang D; Zhang W; Kalfa TA; Grabowski G; Davies S; Malik P; Pan D
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19958-63. PubMed ID: 19903883
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.
Di Domenico C; Villani GR; Di Napoli D; Reyero EG; Lombardo A; Naldini L; Di Natale P
Hum Gene Ther; 2005 Jan; 16(1):81-90. PubMed ID: 15703491
[TBL] [Abstract][Full Text] [Related]
5. Heparan sulfate inhibits hematopoietic stem and progenitor cell migration and engraftment in mucopolysaccharidosis I.
Watson HA; Holley RJ; Langford-Smith KJ; Wilkinson FL; van Kuppevelt TH; Wynn RF; Wraith JE; Merry CL; Bigger BW
J Biol Chem; 2014 Dec; 289(52):36194-203. PubMed ID: 25359774
[TBL] [Abstract][Full Text] [Related]
6. Retrovirus-mediated transfer of the human alpha-L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts.
Huang MM; Wong A; Yu X; Kakkis E; Kohn DB
Gene Ther; 1997 Nov; 4(11):1150-9. PubMed ID: 9425437
[TBL] [Abstract][Full Text] [Related]
7. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector.
Kobayashi H; Carbonaro D; Pepper K; Petersen D; Ge S; Jackson H; Shimada H; Moats R; Kohn DB
Mol Ther; 2005 May; 11(5):776-89. PubMed ID: 15851016
[TBL] [Abstract][Full Text] [Related]
8. In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors.
Di Natale P; Di Domenico C; Villani GR; Lombardo A; Follenzi A; Naldini L
Eur J Biochem; 2002 Jun; 269(11):2764-71. PubMed ID: 12047386
[TBL] [Abstract][Full Text] [Related]
9. Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy.
Di Domenico C; Di Napoli D; Gonzalez Y Reyero E; Lombardo A; Naldini L; Di Natale P
Hum Gene Ther; 2006 Nov; 17(11):1112-21. PubMed ID: 17044753
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Testing of the Safety and Tolerability of Lentiviral Vector-Mediated Above-Normal Alpha-L-Iduronidase Expression in Murine and Human Hematopoietic Cells Using Toxicology and Biodistribution Good Laboratory Practice Studies.
Visigalli I; Delai S; Ferro F; Cecere F; Vezzoli M; Sanvito F; Chanut F; Benedicenti F; Spinozzi G; Wynn R; Calabria A; Naldini L; Montini E; Cristofori P; Biffi A
Hum Gene Ther; 2016 Oct; 27(10):813-829. PubMed ID: 27431943
[TBL] [Abstract][Full Text] [Related]
11. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene.
Hartung SD; Frandsen JL; Pan D; Koniar BL; Graupman P; Gunther R; Low WC; Whitley CB; McIvor RS
Mol Ther; 2004 Jun; 9(6):866-75. PubMed ID: 15194053
[TBL] [Abstract][Full Text] [Related]
12. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation.
Keeling KM; Brooks DA; Hopwood JJ; Li P; Thompson JN; Bedwell DM
Hum Mol Genet; 2001 Feb; 10(3):291-9. PubMed ID: 11159948
[TBL] [Abstract][Full Text] [Related]
13. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow.
Zheng Y; Rozengurt N; Ryazantsev S; Kohn DB; Satake N; Neufeld EF
Mol Genet Metab; 2003 Aug; 79(4):233-44. PubMed ID: 12948739
[TBL] [Abstract][Full Text] [Related]
14. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency.
Lutzko C; Kruth S; Abrams-Ogg AC; Lau K; Li L; Clark BR; Ruedy C; Nanji S; Foster R; Kohn D; Shull R; Dubé ID
Blood; 1999 Mar; 93(6):1895-905. PubMed ID: 10068662
[TBL] [Abstract][Full Text] [Related]
15. Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients.
Oussoren E; Keulemans J; van Diggelen OP; Oemardien LF; Timmermans RG; van der Ploeg AT; Ruijter GJ
Mol Genet Metab; 2013 Aug; 109(4):377-81. PubMed ID: 23786846
[TBL] [Abstract][Full Text] [Related]
16. α- L-iduronidase gene-based therapy using the phiC31 system to treat mucopolysaccharidose type I mice.
Stilhano RS; Martin PK; de Melo SM; Samoto VY; Peres GB; da Silva Michelacci YM; da Silva FH; Pereira VG; D'Almeida V; da Cruz AT; Jasiulionis MG; Han SW
J Gene Med; 2015; 17(1-2):1-13. PubMed ID: 25597593
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model.
Visigalli I; Delai S; Politi LS; Di Domenico C; Cerri F; Mrak E; D'Isa R; Ungaro D; Stok M; Sanvito F; Mariani E; Staszewsky L; Godi C; Russo I; Cecere F; Del Carro U; Rubinacci A; Brambilla R; Quattrini A; Di Natale P; Ponder K; Naldini L; Biffi A
Blood; 2010 Dec; 116(24):5130-9. PubMed ID: 20847202
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
Lutzko C; Omori F; Abrams-Ogg AC; Shull R; Li L; Lau K; Ruedy C; Nanji S; Gartley C; Dobson H; Foster R; Kruth S; Dubé ID
Hum Gene Ther; 1999 Jun; 10(9):1521-32. PubMed ID: 10395377
[TBL] [Abstract][Full Text] [Related]
19. Platelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler syndrome.
Dai M; Han J; El-Amouri SS; Brady RO; Pan D
Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2680-5. PubMed ID: 24550296
[TBL] [Abstract][Full Text] [Related]
20. Mobilization and transduction of peripheral blood progenitor cells in patients with mucopolysaccharidosis I.
Hubel A; Stroncek D; Pan D; Whitley CB; McCullough J
J Hematother; 1998 Dec; 7(6):505-14. PubMed ID: 9919944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
